Abstract 17P
Background
In Australia, Indigenous people are natives and custodians of land. The mortality risk is more than double in Indigenous breast cancer women as compared to non- Indigenous women but carries lower incidence risk. Between 2001 and 2010 Indigenous Western Australian women who developed breast cancer were four times more likely to die of the disease than non-Indigenous women of the same age. The data is scarce but many factors are being studied. The effect of remoteness on mortality of indigenous women still needed to be established. The aim is to analyse remoteness as a factor causing effect on survival in Indigenous breast cancer women.
Methods
The data is collected retrospectively from Western Australian cancer Registry mostly, among other sources. A cohort of 100 patients was selected from database including half of indigenous and half non-indigenous women (1:1). At time of writing, 37 Indigenous and 33 Non–Indigenous breast cancer women data was available. The data collected, to analyze the median survival time (months) of patients with respect to Distance (Metropolitan vs Rural) and Indigenous & Non-Indigenous status.
Results
In survival analysis, it has been observed that both indigenous and non-indigenous who live in metropolitan showed better 10 year survival ; 184 months while who were in rural area showed reduced median survival time 130 months and differences among them was found to be significant (p = 0.03), suggesting better survival was associated with patients who live in metropolitan area. However, on analyzing the survival of Indigenous patients with respect to distance, it wasn’t statistically significant (p = 0.19) but still showed higher median survival for patients living in metropolitan area (153 months) as compared to remote rural areas (110 months). Further analyzing indigenous breast cancer patients outcomes with respect to metro area (153 months), 1000km or less and greater then 1000km (87 months); higher survival benefit trend for patient’s living close to metro area.
Conclusions
The data suggest that the Indigenous breast cancer women have inferior survival outcomes with respect to distance from metropolitan area, highlighting a strong co-relation of remoteness and survival disadvantage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Khan, A. Redfern.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract
328P - A retrospective analysis of patients with non-small cell lung cancer who developed drug-induced lung disorder by immune checkpoint inhibitors
Presenter: Fumiko Hayashi
Session: Poster display session
Resources:
Abstract